In the meantime, Jefferies downgraded its Lyra Therapeutics Inc [LYRA] rating to a Hold from a a Buy in a research note published on May 07, 2024; the price target was decreased to $0.50 from $10. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in early May from “a Buy” to “a Neutral”. BofA Securities also remained covering LYRA and has decreased its forecast on May 07, 2024 with a “an Underperform” recommendation from previously “Buy” rating. William Blair revised its rating on May 06, 2024. It rated LYRA as “a Mkt perform” which previously was an “an Outperform”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance Review of LYRA
On Tuesday, Lyra Therapeutics Inc [NASDAQ:LYRA] saw its stock jump 16.56% to $0.20. Over the last five days, the stock has lost -28.84%. Lyra Therapeutics Inc shares have fallen nearly -96.27% since the year began. Nevertheless, the stocks have fallen -93.30% over the past one year. While a 52-week high of $6.79 was reached on 03/27/24, a 52-week low of $0.16 was recorded on 11/18/24. SMA at 50 days reached $0.2487, while 200 days put it at $1.8716.
Levels Of Support And Resistance For LYRA Stock
The 24-hour chart illustrates a support level at 0.1699, which if violated will result in even more drops to 0.1442. On the upside, there is a resistance level at 0.2151. A further resistance level may holdings at 0.2346. The Relative Strength Index (RSI) on the 14-day chart is 38.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0598, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.20%. Stochastics %K at 11.53% indicates the stock is a buying.
How much short interest is there in Lyra Therapeutics Inc?
A steep rise in short interest was recorded in Lyra Therapeutics Inc stocks on 2024-10-31, dropping by -0.81 million shares to a total of 2.04 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 2.85 million shares. There was a decline of -39.85%, which implies that there is a negative sentiment for the stock.
